FDA Approves World’s First Long-Term Implantable Continuous Glucose Monitoring System for Marketing in United States

GERMANTOWN, Md., June 21, 2018 — Senseonics Holdings, Inc. (NYSE American: SENS) today announced the U.S. Food and Drug Administration has approved its Pre-market Approval (PMA) application to market the company’s Eversense® Continuous Glucose Monitoring (CGM) System to people with diabetes in the United States. The system is the first and only CGM system to feature an implantable glucose sensor and provide long-term continuous monitoring for up to three months.

Click here to read the official press release in full.

 

By |2018-06-21T15:22:25+00:00June 21st, 2018|Uncategorized|0 Comments

About the Author:

Leave A Comment